抄録
Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 182-188 |
| ページ数 | 7 |
| ジャーナル | Cytokine |
| 巻 | 111 |
| DOI | |
| 出版物ステータス | 出版済み - 11 2018 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
- Biochemistry
- Hematology
- Molecular Biology
これを引用
Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis. / Furue, Kazuhisa; Ito, Takamichi; Furue, Masutaka.
：: Cytokine, 巻 111, 11.2018, p. 182-188.研究成果: ジャーナルへの寄稿 › 評論記事
}
TY - JOUR
T1 - Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis
AU - Furue, Kazuhisa
AU - Ito, Takamichi
AU - Furue, Masutaka
PY - 2018/11
Y1 - 2018/11
N2 - Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.
AB - Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.
UR - http://www.scopus.com/inward/record.url?scp=85052470976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052470976&partnerID=8YFLogxK
U2 - 10.1016/j.cyto.2018.08.025
DO - 10.1016/j.cyto.2018.08.025
M3 - Review article
C2 - 30172115
AN - SCOPUS:85052470976
VL - 111
SP - 182
EP - 188
JO - Cytokine
JF - Cytokine
SN - 1043-4666
ER -